Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBR8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for STELARA 90 mg/ml syringes. This firm fixed-price delivery order was issued on January 28, 2026, with an ultimate completion date of February 19, 2026, and carries no set-aside designation. The award reflects DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement and its established role as a critical supplier within the Department of Defense pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, positions the company as one of multiple regional prime vendor contractors supporting DoD military healthcare facilities worldwide. The PPV-G GEN V represents part of a broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across the federal military medical system, enabling DLA to issue firm fixed-price delivery orders for diverse pharmaceutical products including branded and generic medications, biologics, and medical consumables to support recurring medical supply needs globally.
Quick answers
Who was awarded contract SPE2DR26FGBR8?
SPE2DR26FGBR8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FGBR8 worth?
The government has obligated $16,584 on SPE2DR26FGBR8.
Is contract SPE2DR26FGBR8 an order under another contract?
Yes. SPE2DR26FGBR8 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBR8 competed?
The extent of competition for SPE2DR26FGBR8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award